LDLR and metabolic dysfunction-associated steatohepatitis: For example, PPARδ-selective agonist L-165041 treatment improved steatosis and inflammation in LDLR−/− mice fed Western diet [38], another PPARδ agonist GW501516 improved hepatic inflammation in a non-alcoholic steatohepatitis model [39], and yet another PPARδ agonist GW0742 reduced copper-induced liver damage [40].